News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2022

Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

EQS-News: Epigenomics AG / Key word(s): StudyEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test 19.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data […]

Read more

Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs

Epigenomics AG / Key word(s): Change in Forecast/ForecastEpigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs 19-Sep-2022 / 10:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS – a service of EQS Group […]

Read more

Epigenomics AG: Capital reduction planned at a ratio of 4 : 1

Epigenomics AG / Key word(s): Corporate Action/AGM/EGM Epigenomics AG: Capital reduction planned at a ratio of 4 : 1 09-Sep-2022 / 19:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content […]

Read more

Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/AGM/EGMEpigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG 15.08.2022 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG Berlin, August 15, 2022 – The Executive Board of Epigenomics AG […]

Read more

​​​​​​​Epigenomics AG Reports Financial Results for the First Six Months of 2022

DGAP-News: Epigenomics AG / Key word(s): Half Year Report/Half Year Results​​​​​​​Epigenomics AG Reports Financial Results for the First Six Months of 2022 10.08.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Six Months of 2022 Berlin (Germany) and San Diego, CA (U.S.A.), […]

Read more

Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG / Total Voting Rights AnnouncementEpigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 19.07.2022 / 13:10 Total Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Publication […]

Read more